|
DE19921567A1
(de)
*
|
1999-05-11 |
2000-11-16 |
Basf Ag |
Verwendung von Phthalazine-Derivaten
|
|
EP1634605A3
(en)
|
2000-03-08 |
2006-10-11 |
Novo Nordisk A/S |
treatment of dyslipidemia in a patient having type 2 diabetes
|
|
EP1444219A1
(en)
|
2001-10-12 |
2004-08-11 |
Novo Nordisk A/S |
Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
|
|
IL162620A0
(en)
|
2001-12-21 |
2005-11-20 |
Novo Nordisk As |
Amide derivatives as gk activators
|
|
DE60335359D1
(de)
*
|
2002-04-30 |
2011-01-27 |
Kudos Pharm Ltd |
Phthalazinonderivate
|
|
PL215132B1
(pl)
|
2002-06-27 |
2013-10-31 |
Novo Nordisk As |
Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
|
|
WO2005030797A2
(en)
|
2003-09-30 |
2005-04-07 |
Novo Nordisk A/S |
Melanocortin receptor agonists
|
|
EP2298337B1
(en)
|
2003-12-09 |
2017-02-22 |
Novo Nordisk A/S |
Regulation of food preference using GLP-1 agonists
|
|
PT1723128E
(pt)
|
2004-01-06 |
2013-02-27 |
Novo Nordisk As |
Heteroaril-ureias e o seu uso como activadores da glicoquinase
|
|
US20080113944A1
(en)
|
2004-05-04 |
2008-05-15 |
Novo Nordisk A/S |
Novel Indole Derivatives
|
|
EP1758575A1
(en)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
|
US8263551B2
(en)
|
2004-11-22 |
2012-09-11 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
|
CN101137631A
(zh)
|
2004-12-03 |
2008-03-05 |
转化技术制药公司 |
杂芳族葡糖激酶激活剂
|
|
CA2614116A1
(en)
|
2005-07-04 |
2007-01-11 |
Novo Nordisk A/S |
Novel medicaments
|
|
KR101446973B1
(ko)
|
2005-07-14 |
2014-10-07 |
트랜스테크 파르마 엘엘씨 |
우레아 글루코키나제 활성제
|
|
EP1910317B1
(en)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
1-amino linked compounds
|
|
SI1951658T1
(sl)
|
2005-11-17 |
2012-11-30 |
Lilly Co Eli |
Antagonisti glukagonskega receptorja priprava interapevtska uporaba
|
|
NZ570524A
(en)
|
2006-03-28 |
2011-08-26 |
High Point Pharmaceuticals Llc |
Benzothiazoles having histamine H3 receptor activity
|
|
PT2079732E
(pt)
|
2006-05-29 |
2012-02-02 |
High Point Pharmaceuticals Llc |
3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)- piridazina, os seus sais e solvatos e a sua utilização a título de antagonista do receptor h3 de histamina
|
|
EP2086951B1
(en)
|
2006-11-15 |
2011-12-21 |
High Point Pharmaceuticals, LLC |
Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
|
|
CA2669884A1
(en)
|
2006-11-15 |
2008-05-22 |
High Point Pharmaceuticals, Llc |
Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
|
|
EP2099777B1
(en)
|
2007-01-11 |
2015-08-12 |
Novo Nordisk A/S |
Urea glucokinase activators
|
|
EP2539364A1
(en)
|
2010-02-26 |
2013-01-02 |
Novo Nordisk A/S |
Peptides for treatment of obesity
|
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
|
WO2011117415A1
(en)
|
2010-03-26 |
2011-09-29 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
US10130684B2
(en)
|
2011-02-03 |
2018-11-20 |
Pharmedica Ltd. |
Oral dissolving films for insulin administration, for treating diabetes
|
|
JP2014510739A
(ja)
|
2011-03-28 |
2014-05-01 |
ノヴォ ノルディスク アー／エス |
新規のグルカゴン類似体
|
|
CA2849673A1
(en)
|
2011-09-23 |
2013-03-28 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
WO2014170496A1
(en)
|
2013-04-18 |
2014-10-23 |
Novo Nordisk A/S |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
|
JP2017525656A
(ja)
|
2014-06-04 |
2017-09-07 |
ノヴォ ノルディスク アー／エス |
医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
|
|
CN111032680A
(zh)
|
2017-03-15 |
2020-04-17 |
诺和诺德股份有限公司 |
能够与黑皮质素4受体结合的双环化合物
|
|
US20210221867A1
(en)
|
2018-05-15 |
2021-07-22 |
Novo Nordisk A/S |
Compounds Capable of Binding to Melanocortin 4 Receptor
|
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|